Home
overview
Emerging bacterial resistance is a world-wide problem that has proven itself problematic for a number of years contributing to a growing market for anti-infective drugs capable of combating these infectious pathogens. As a key industry representative, you are aware of the commercial possibilities of this sector and how the constant evolution of the ‘Superbugs’ sustains an anti-infective industry.

For our part, as world-leaders in pharmaceutical conferences, SMi’s ‘Superbugs and Superdrugs: An update on Anti-Infectives’ conference has identified Superbugs and the anti-infectives used to combat these bacterial pathogens. This conference is an opportunity waiting to be exploited.

Why you should attend this event? This is your chance to hear the experts in this field discussing their latest approaches and achievements to new or improved antibiotics. They will stress the urgent need of new antibiotics and discuss ongoing work in this field. This conference offers you the advantage of meeting key players all under one roof - giving you fantastic networking opportunities.

Conference programme

8:30 Registration & Coffee

9:00 Chairman’s Opening Remarks

Prof. Ian Chopra

Prof. Ian Chopra, Director of Research, Antimicrobial Research Centre, University of Leeds

9:10 SUPERBUGS: AN OVERVIEW

John F Barrett

John F Barrett, Executive Director, Microbiology, Anti-Infectives Discovery, Bristol Myers Squibb

  • Re-emerging infectious diseases
  • Antibiotic resistance and the need for new therapies
  • Emerging therapies to address this issue
  • How are we placed to tackle these pathogens?
  • 9:40 CHALLENGES IN DRUG DEVELOPMENT

    Dr Rudolf Then

    Dr Rudolf Then, Head, Infectious Disease Research, Hoffmann-La Roche

  • The global view
  • Local situations; Problem organisms
  • What are the needs?
  • Solutions and future developments
  • Strengths and weaknesses of new antibiotics in development; New antibiotics in early stages: selected examples
  • Non-antibiotic therapeutic strategies
  • 10:20 MCA: EVALUATION OF NEW ANTI-INFECTIVES

    Dr Mair Powell

    Dr Mair Powell, Senior Medical Officer, Medicines Control Agency

  • Drug resistant bacteria are a concern for the licensing authorities
  • Recent experience with EU procedures for approval of new agents
  • Approval times: potential use of fast-tracking mechanisms
  • Guidelines relevant to antibacterial development programmes
  • Examples of difficulties in interpretation of safety and efficacy data
  • Insertion / updating of prevalence of resistance data in the EU SPC
  • 11:00 Morning Coffee

    11:20 DRUG EVALUATION AND RESEARCH

    Dr Clyde Thornsberry

    Dr Clyde Thornsberry, Director, MRL Pharmaceutical Services

  • Drug resistant bacteria: an urgent problem
  • Recent experience with US procedures for approval of new agents
  • Bringing new drugs to market quickly to combat resistant pathogens
  • Shortening the drug development process
  • Guidelines on trial design
  • Getting faster drug approval
  • 12:00 MULTIPLE DRUG RESISTANCE IN ESCHERICHIA COLI

    Dr Laura Piddock

    Dr Laura Piddock, Lecturer in Anti-Infectives, Birmingham University, UK

  • Role of mutations in genes mediating target proteins, DNA gyrase and DNA topoisomerase IV
  • Role of changes in the cell envelope
  • Role of decreased accumulation and effluxaccumulation and efflux
  • Role of increased expression of genes that encode efflux pumps or multiple drug resistance
  • 12:40 Networking Lunch

    14:00 A RESPONSE TO DRUG RESISTANT BACTERIA

    Dr Mark Nelson

    Dr Mark Nelson, Senior Director of Chemistry, Paratek Pharmaceuticals

  • The need for improved antibacterial agents
  • Effective anti-bacterials against MRSA and WRE
  • Chemical rationale
  • 14:40 PHARMACOKINETIC/PHARMACODYNAMIC MODELLING

    Dr Christine Falcoz

    Dr Christine Falcoz, Principle Clinical Pharmacologist, Experimental Medicine, Anti-Infectives, GlaxoWellcome

  • PK/PD as a guide for an integrated development of anti infectives (decision-making)
  • In vivo and in vitro methodologies in animals and man,
  • Site of infection
  • Compound selection at early stages
  • Prediction of likely efficacious dosing regimens in humans (dose-rationale)
  • Integration to the clinical development; Regulatory considerations
  • 15:20 Afternoon Tea

    15:40 SIGA’S RESPONSE TO A GLOBAL CRISIS

    Dr Dennis Hruby

    Dr Dennis Hruby, Vice President, Research, Siga Pharmaceuticals

  • Bacterial adhesion strategies
  • Gram positive: sortase
  • Gram negative: pilicides
  • DepP-a broad spectrum target
  • 16:20 THE CHALLENGE OF ANTI-BACTERIAL DRUG DISCOVERY

    Dr Stefan Wohlfeil

    Dr Stefan Wohlfeil, Vice President, Anti-Infectives, Bayer

  • Novel fluoro-quinolone agents with improved target potency and resistance profile
  • Revisiting underexplored lead structures: is there a second chance for optimisation with new technologies?
  • The use of genomics in antibacterial drug discovery
  • Antibacterial research in the post-genomic era
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Networking Drinks Reception

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Jos Van der Meer

    Dr Jos Van der Meer, Head, Department of General Internal Medicine, University Medical Center, Nymegen

    9:10 THE MRSA QUESTION

    Dr Andre Bryskier

    Dr Andre Bryskier, Head, Anti-Infectives, Aventis

  • Infection control strategies
  • Synercid: a new class of antibiotic
  • Mode of delivery
  • Current clinical trial status
  • 9:40 TARGETED TREATMENT

    Dr Stephen Carroll

    Dr Stephen Carroll, Vice President, Preclinical Research, Xoma

  • Exploiting genomic information to aid drug development
  • The technologies employed
  • The concept of NEUPREX
  • Mode of action of NEUPREX
  • Collaborations in drug development
  • 10:20 CUBIST PHARMACEUTICALS UPDATE

    Dr George Shimer

    Dr George Shimer, Senior Director, Pathogen Genomics, Cubist Pharmaceuticals

  • Developing daptomycin
  • Selecting the proper dose for an antibiotic; Rapid killing of a wide range of resistant strains
  • Pharmacokinetic separation of efficacy and toxicity; Review clinical data
  • VITA technology
  • validating unique targets
  • identifying additional compounds; spectrum of activity against MRSA and VRE
  • 11:00 Morning Coffee

    11:20 NEW GENERATION DRUG DISCOVERY

    Dr Carl Craft

    Dr Carl Craft, Head Macrolide Venture, Abbott Laboratories

  • Development trends amongst Macrolides
  • Opportunities for ketolides
  • The ketolide antibiotic: ABT-773
  • Mechanism of action
  • Decreasing the rate of drug resistance
  • 12:00 NEW GENERATION DRUG DEVELOPMENT

    Dr Bob Naso

    Dr Bob Naso, Senior Vice President, Research & Development, NABI

  • The growing problem of Gram-positive bacterial infections
  • New vaccines and drugs from NABI to combat the problem
  • StaphVAX (S. aureus conjugate polysaccharide vaccine); Results of phase III clinical trials in haemodialysis patients
  • Altastaph (S. aureus immune globulin, Human); Results of phase I/II clinical trials in low birth weight neonates
  • EpiVAX (S. epidermidis conjugate vaccine) - preclinical results
  • EnteroVAX (E. faecalis conjugate vaccine) - preclinical results
  • 12:40 Lunch

    13:40 ANTI INFECTIVE DRUGS BASED ON THE QUORUM SYSTEM

    Dr Jeffrey Stein

    Dr Jeffrey Stein, Vice President, Chief Scientific Officer, Quorex Pharmaceuticals

  • A novel gene highly conserved pathway regulating virulance in Gram positive and Gram negative pathogens
  • Powerful new bioinformanics tools that have enabled target characterisation and design
  • Compounds that inhibit virulance broadly
  • Dramatic potentiation of existing bacteriocidal drugs
  • Inhibition of biofilm formation
  • 14:20 REVIEWING THE IMPACT OF BACTERIAL GENOMICS

    Dr Hannes Loferer

    Dr Hannes Loferer, Senior Director, Microbiology, GPC Biotech

  • Genomics and target discovery: large-scale genetics; comparative genomics; genes of unknown function
  • Genomics and assay development; Surrogate markers; Surrogate ligands; Protein-protein interaction technologies
  • Genomics and drug development; Reverse genomics and compound mode of action
  • 15:00 NEW SCREENS FOR NOVEL ANTIBIOTICS

    Dr Christian Fritz

    Dr Christian Fritz, Senior Scientist, Anti-Infectives, Millennium Pharmaceuticals

  • From gene discovery to screen development
  • Development assays for targets of unknown function
  • Pathway screens
  • Use of transcriptional profiling in assay development
  • Promising individual targets
  • 15:40 Afternoon Tea

    16:00 FUNCTIONAL PROTEOMICS

    Dr Robert Bargetze

    Dr Robert Bargetze, Vice President, Research & Development, Ligocyte

  • The ProteoFlow system
  • Mechanism of action of model
  • Discovery of broad platform technologies
  • Functional genomics capabilities to identify and validate genes and proteins
  • Results: validated targets for the discovery of drugs to combat resistant bacteria.
  • 16:30 NEW GENERATION DRUG DISCOVERY

    Dr Scott Mills

    Dr Scott Mills, Scientist, Molecular Sciences, AstraZeneca

  • Using genomic information in the antimicrobial drug discovery process
  • Bioinformatic tools for comparative genomic analysis
  • Target identification in silico
  • Target validation through functional genomics/genetics
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Deal Making Opportunities
    Workshop

    Deal Making Opportunities

    The Hatton, at etc. venues
    7th March 2001
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.